The digitalization of medicine promises great advances for global health. Combined with three-dimensional (3D) printing technology, noncontact optical scanner, and computer-aided design, we can make personalized 3D printing scoliosis orthosis for patients across the country – with better diagnostics, personalized treatments, and early disease prevention. We hope optimize the production process of scoliosis orthotics, improve the production efficiency of orthotics, and promote the clinical transformation of 3D-printed scoliosis orthosis. To standardize the design, manufacture, materials, and clinical applications of 3D printing technology in the scoliosis orthosis, Chinese experts in relevant fields were organized to formulate this expert consensus.

Digitalizing clinical trials provide an opportunity to address challenges faced in the Phase I trial settings, where near real-time data capture and data interpretation are prerequisites for iterative decision-making to rapidly adapt trial designs based on emerging insights. Although digital technologies have driven significant improvements in many businesses and organizations, the adoption of digital technologies in clinical trials has been slow. In recognition of this lag, the UpSMART consortium, a 5-year funded program (2020–2024), has been established in Europe between the UK, Spain, and Italy to embrace digital technologies and drive benefits to patients. The consortium, led by the Cancer Research UK Manchester Institute Cancer Biomarker Centre, aims to 'digitalize' Experimental Cancer Medicine Centres in the UK and Early Drug Development Units in Spain and Italy by open-sourcing and sharing digital healthcare products between participating centers across the consortium. The goal is to optimize data capture and interpretation thus accelerating Phase I clinical research to ultimately benefit patients by allowing faster access to tomorrow's medicines.